Gastrointestinal Stromal Tumours (GIST) - development in pathology, surgery and medical therapy Developed during the 10th German GIST-meeting, Gottingen

被引：4

作者：

Agaimy, A. ^{[1
]}

Bauer, S. ^{[2
]}

Beham, A. ^{[3
]}

Bertolini, J. ^{[4
]}

Haller, F. ^{[1
]}

Koschny, R. ^{[5
]}

Maier, J. ^{[6
]}

Montemurro, M. ^{[7
]}

Perez, D. ^{[8
]}

Schaefer, I-M ^{[9
]}

Schildhaus, H-U ^{[10
]}

Wurst, C. ^{[11
]}

Cameron, S. ^{[12
]}

机构：

[1] Univ Erlangen Nurnberg, Pathol, Nurnberg, Germany

[2] Univ Klin Essen, Innere Klin Tumorforsch, Essen, Germany

[3] Univ Med Gottingen, Allgemein Viszeral & Kinderchirurg, Gottingen, Germany

[4] Univ Hamburg, Inst Pathol, Hamburg, Germany

[5] Heidelberg Univ, Med Klin 4, D-69115 Heidelberg, Germany

[6] Univ Leipzig, Hamatol & Hamostaseol, D-04109 Leipzig, Germany

[7] Royal Marsden Hosp, Sarcoma Unit, London, England

[8] Univ Hamburg, Allgemein Viszeral & Thoraxchirurg, Hamburg, Germany

[9] Brigham & Womens Hosp, Pathol, Boston, MA 02115 USA

[10] Univ Med Gottingen, Pathol, Gottingen, Germany

[11] Univ Klinikum Jena, Allgemein & Viszeralchirurg, Jena, Germany

[12] Univ Med Gottingen, Gastroenterol & Endokrinol, D-37075 Gottingen, Germany

来源：

ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2015年 / 53卷 / 03期

关键词：

gastrointestinal stromal tumours (GIST); gastro-entero-pancreatic tumours; stomach; intestines; ADJUVANT IMATINIB MESYLATE; PROGNOSTIC-FACTORS; RISK-FACTORS; C-KIT; MUTATIONS; RESISTANT; METASTASECTOMY; RECURRENCE; MORPHOLOGY; MASITINIB;

D O I：

10.1055/s-0034-1385711

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The first description of ligand-independent activating mutations in the KIT gene, which encodes the tyrosine-kinase KIT, greatly improved our understanding of gastrointestinal stromal tumour (GIST) biology. The therapeutic success in GIST has made tyrosine kinase inhibitors a "paradigm of targeted therapy". Deciphering resistance mechanisms in GIST has had implications for many other kinase-driven cancers. To exchange current knowledge within the field of GIST, the German GIST Meeting has taken place for now 10 years, traditionally in Gottingen. Subjects discussed include clinical diagnostics, pathology, surgery, and medical therapy. The following presentation gives an overview of the last meeting held in December 2013, including distinctive features in GIST and current data on the different topics.

引用

页码：235 / 243

页数：9

共 2 条

[1] Emergency surgery due to complications during molecular targeted therapy in advanced gastrointestinal stromal tumors (GIST)
Ruka, W.
Rutkowski, P.
Nowecki, Z.
Dziewirski, W.
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 27 - 27
[2] IDENTIFYING BIOLOGICAL AND CLINICAL CHARACTERISTICS OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS (GIST) RESPONDING TO IMATINIB THERAPY FOR MORE THAN 5 AND 10 YEARS
Bosma, J.
Verboom, M.
Gataa, I.
Werkhoven, E. V.
Gelderblom, H.
Mathijssen, R. H. J.
Reyners, A. K. L.
Osuch, C.
Siedlecki, J. A.
Kubackova, K.
Kocakova, I.
Bylina, E.
Le Cesne, A.
Rutkowski, P.
Steeghs, N.
ANNALS OF ONCOLOGY, 2014, 25

← 1 →